Business Wire (Free subscription) | 11/04/2009
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (NYSE: MRK) today outlined its global plans following the completion of Merck's merger with Schering-Plough Corporation announced yesterday. The new Merck is a global health care leader aimed at providing innovative, distinctive products and services that save and improve lives, while satisfying customer needs and creating long term shareholder...
The Earth Times Online Newspaper (Free subscription) | 11/03/2009
WHITEHOUSE STATION, N.J. & KENILWORTH, N.J. - Merck & Co., Inc. (NYSE: MRK) and Schering-Plough Corporation (NYSE: SGP) today announced that they will complete their merger shortly after 4:00PM ET today. The companies will begin combined operations tomorrow, November 4, 2009.
Business Wire (Free subscription) | 11/03/2009
WHITEHOUSE STATION, N.J. & KENILWORTH, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (NYSE: MRK) and Schering-Plough Corporation (NYSE: SGP) today announced that they will complete their merger shortly after 4:00PM ET today. The companies will begin combined operations tomorrow, November 4, 2009. As previously announced, Schering-Plough will change its name to Merck and its common stock will trade...
Medical News Today (Free subscription) | 11/03/2009
Schering-Plough Corporation (NYSE: SGP) announced that its investigational sublingual Grass (Phleum Pratense) Allergy Immunotherapy Tablet (AIT) has met the primary endpoint in a Phase III study of adult subjects in the U.S. with a history of grass pollen induced rhinoconjunctivitis with or without asthma.
Medical News Today (Free subscription) | 11/03/2009
Schering-Plough Corporation (NYSE: SGP) reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.
PR News Wire (Free subscription) | 11/02/2009
KENILWORTH, N.J., Nov. 2 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced it has initiated sponsorship of two projects in India to reduce the incidence of human and animal rabies through improved educational awareness and mass vaccination of dogs. The company will donate $200,000 and rabies vaccine from Intervet/Schering-Plough as well as share expertise with partners...
Red Orbit (Free subscription) | 11/02/2009
KENILWORTH, N.J., Nov. 2 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that its investigational sublingual Grass (Phleum Pratense) Allergy Immunotherapy Tablet (AIT) has met the primary endpoint in a Phase III study of adult subjects in the U.S.
PR News Wire (Free subscription) | 11/01/2009
BOSTON, Nov. 1 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported two data presentations supporting response guided therapy with boceprevir combination therapy in patients with chronic hepatitis C virus (HCV) genotype 1. These retrospective analyses were presented at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov....
The Earth Times Online Newspaper (Free subscription) | 10/29/2009
WHITEHOUSE STATION, N.J. & KENILWORTH, N.J. - Merck & Co., Inc. (NYSE: MRK) and Schering-Plough Corporation (NYSE: SGP) today announced that they have received clearance from the U.S. Federal Trade Commission (FTC), the Swiss Competition Commission and the Canadian Competition Bureau
Business Wire (Free subscription) | 10/29/2009
WHITEHOUSE STATION, N.J. & KENILWORTH, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (NYSE: MRK) and Schering-Plough Corporation (NYSE: SGP) today announced that they have received clearance from the U.S. Federal Trade Commission (FTC), the Swiss Competition Commission and the Canadian Competition Bureau for their proposed merger. The companies said that the FTC terminated the waiting period under...
Reuters UK (Free subscription) | 10/29/2009
NEW YORK, Oct 29 (Reuters) - Time Warner Inc said on Thursday that Schering Plough Corp Chief Executive Fred Hassan has been elected to its board.
Business Wire (Free subscription) | 10/29/2009
NEW YORK--(BUSINESS WIRE)--Time Warner Inc. (NYSE: TWX) announced that its Board of Directors has elected Fred Hassan to join the Board, effective today. Mr. Hassan, 63, is Chairman of the Board and Chief Executive Officer of Schering-Plough Corporation. Jeff Bewkes, Chairman and CEO of Time Warner, said: “Fred Hassan is an experienced CEO who brings to our Board more than 15 years of leading...
The Earth Times Online Newspaper (Free subscription) | 10/23/2009
WHITEHOUSE STATION, N.J. & KENILWORTH, N.J. - Merck & Co., Inc. (NYSE: MRK) and Schering-Plough Corporation (NYSE: SGP) today announced that they have received clearance from the European Commission (EC) under the EC Merger Regulation for their proposed merger. &ldquo
Business Wire (Free subscription) | 10/23/2009
WHITEHOUSE STATION, N.J. & KENILWORTH, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (NYSE: MRK) and Schering-Plough Corporation (NYSE: SGP) today announced that they have received clearance from the European Commission (EC) under the EC Merger Regulation for their proposed merger. “Approval from the European Commission marks a key milestone for the completion of our transaction with Schering-Plough,”...
SeekingAlpha.com (Free subscription) | 10/22/2009
Schering-Plough Corporation ( SGP ) Q3 2009 Earnings Call October 22, 2009 7:15 am ET Complete Story »
The 2 latest articles published by users on Schering-Plough Corporation :
aarkstore | 07/29/2009
Schering-Plough Corporation - SWOT Analysis company profile is the essential source for top-level company data and information. Schering-Plough Corporation - SWOT Analysis examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy. Schering-Plough, which signed a $41.1 billion merger agreement with its Big...
anonymous (Free subscription) | 03/10/2009
Drugmakers Merck & Co. and Schering-Plough Corp. are planning to merge under the name Merck in a stock-and-cash deal worth about $41.1, If Merck merges with Schering-Plough , could Johnson & Johnson gain control of Schering’s blockbuster drug Remicade?, And much Details here. Source page : http://time2masti.blogspot.com/2009/03/merck-schering-plough-merger.html
Videos